Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 2/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.39 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239775 | 1.00 | PABPC1 (0.39) | PABPC1APOBEC3AEIF4HAPOBEC3GMEN1 | |
| SCHEMBL1238384 | 1.00 | PABPC1 (0.39) | PABPC1APOBEC3AEIF4HAPOBEC3GMEN1 | |
| SCHEMBL12888485 | 1.00 | PABPC1 (0.39) | PABPC1APOBEC3AEIF4HAPOBEC3GMEN1 | |
| SCHEMBL2921270 | 0.90 | GAA (0.38) | SMN1; SMN2PTGS1DRD2CYP3A4CYP2C9 | |
| SCHEMBL2926613 | 0.90 | GAA (0.38) | SMN1; SMN2PTGS1DRD2CYP3A4CYP2C9 | |
| SCHEMBL5794846 | 0.90 | PPARG (0.45) | PABPC1APOBEC3AEIF4HAPOBEC3GMEN1 | |
| SCHEMBL12888392 | 0.90 | SMN1; SMN2 (0.40) | APOBEC3AAPOBEC3GMEN1KMT2AMAPT | |
| SCHEMBL1238340 | 0.89 | LMNA (0.41) | PABPC1APOBEC3AEIF4HAPOBEC3GMEN1 | |
| SCHEMBL1238324 | 0.89 | LMNA (0.41) | PABPC1APOBEC3AEIF4HAPOBEC3GMEN1 | |
| SCHEMBL12888483 | 0.87 | LMNA (0.43) | PABPC1APOBEC3AEIF4HAPOBEC3GMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879843-B2 | matrix metallo-proteinase inhibitors such as (-)-ethyl 4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate, used for the treatment of osteoarthritis or rheumatoid arthritis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879843-B2 | matrix metallo-proteinase inhibitors such as (-)-ethyl 4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate, used for the treatment of osteoarthritis or rheumatoid arthritis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100009976-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7598240-B2 | Benzothiazin-3-one compound and intermediate therefor | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20080058321-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009976-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | HDAC11, HDAC8, MMP11 | PABPC1 3566/4885APOBEC3A 2705/4885EIF4H 2276/4885 |
| US-20080058321-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | HDAC11, HDAC8, MMP11 | PABPC1 3566/4885APOBEC3A 2705/4885EIF4H 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.